Novel treatment for obsessive-compulsive disorder (OCD) and OCD-related disorders using GVG

Abstract

The present invention relates to the use of gamma vinyl-GABA (GVG) and other GABAergic agents to treat obsessive-compulsive disorder (OCD) and OCD-related disorders, and to reduce or eliminate behaviors associated with obsessive-compulsive disorder (OCD) and OCD-related disorders.

1 . A method for treating a mammal suffering from OCD or OCD-related disorders, comprising administering to said mammal a pharmaceutical composition that includes GVG or a pharmaceutically acceptable salt thereof, or an enantiomer or racemic mixture thereof, to effectively treat said disorders.  
     
     
         2 . The method of  claim 1 , wherein said OCD-related disorder is selected from the group consisting essentially of general anxiety disorder, pathological or compulsive gambling disorder, compulsive eating, body dysmorphic disorder, hypochondriasis, pathologic grooming conditions, kleptomania, pyromania, attention deficit hyperactivity disorder and impulse control disorders.  
     
     
         3 . The method of  claim 1 , wherein said mammal is a human and said composition containing GVG in an amount from about 500 mg/day to about 5000 mg/day.  
     
     
         4 . A method for reducing or eliminating behaviors associated with OCD and OCD-related disorders in a mammal suffering from said disorders, comprising administering to said mammal a pharmaceutical composition that includes GVG or a pharmaceutically acceptable salt thereof, or an enantiomer or racemic mixture thereof, to reduce or eliminate said behaviors.  
     
     
         5 . The method of  claim 4 , wherein said OCD-related disorder is selected from the group consisting essentially of general anxiety disorder, pathological or compulsive gambling disorder, compulsive eating, body dysmorphic disorder, hypochondriasis, pathologic grooming conditions, kleptomania, pyromania, attention deficit hyperactivity disorder and impulse control disorders.  
     
     
         6 . The method of  claim 4 , wherein said mammal is a human and said composition contains GVG in an amount from about 500 mg/day to about 5000 mg/day.  
     
     
         7 . A method for treating a mammal suffering from OCD or OCD-related disorders, comprising administering to said mammal a composition that increases central nervous system GABA levels of said mammal.  
     
     
         8 . The method of  claim 7 , wherein said OCD-related disorder is selected from the group consisting essentially of general anxiety disorder, pathological or compulsive gambling disorder, compulsive eating, body dysmorphic disorder, hypochondriasis, pathologic grooming conditions, kleptomania, pyromania, attention deficit hyperactivity disorder and impulse control disorders.  
     
     
         9 . The method of  claim 7 , wherein said composition is selected from the group consisting essentially of GVG, gabapentin, valproic acid, topiramate, progabide, fengabide, gamma-hydroxybutyric acid, tiagabine, acamprosate, cetyl GABA or a pharmaceutically acceptable salt thereof, or an enantiomer or a racemic mixture thereof.  
     
     
         10 . The method of  claim 7 , wherein said mammal is a human and wherein said composition contains GVG in an amount from about 500 mg/day to about 5000 mg/day.  
     
     
         11 . The method of  claim 7 , wherein said mammal is a human and wherein said composition comprises gabapentin in an amount from about 600 mg/day to about 3600 mg/day.  
     
     
         12 . The method of  claim 7 , wherein said mammal is a human and said composition comprises valproic acid in an amount from about 500 mg/day to about 2500 mg/day.  
     
     
         13 . The method of  claim 7 , wherein said mammal is a human and wherein said composition comprises topiramate in an amount from about 100 mg/day to about 1000 mg/day.  
     
     
         14 . The method of  claim 7 , wherein said mammal is a human and wherein said composition comprises progabide in an amount from about 1000 mg/day to about 3000 mg/day.  
     
     
         15 . The method of  claim 7 , wherein said mammal is a human and wherein said composition comprises fengabine in an amount from about 700 mg/day to about 4000 mg/day.  
     
     
         16 . The method of  claim 7 , wherein said mammal is a human and wherein said composition comprises gamma-hydroxybutyric acid in an amount from about 700 mg/day to about 5000 mg/day.  
     
     
         17 . The method of  claim 7 , wherein said mammal is a human and wherein said composition comprises tiagabine in an amount from about 16 mg/day to about 56 mg/day.  
     
     
         18 . The method of  claim 7 , wherein said mammal is a human and wherein said composition comprises acamprosate in an amount from about 700 mg/day to about 3000 mg/day.  
     
     
         19 . A method for reducing or eliminating behaviors associated with OCD and OCD-related disorders in a mammal suffering from said disorders, comprising administering to said mammal a composition that increases central nervous system GABA levels of said mammal.  
     
     
         20 . The method of  claim 19 , wherein said OCD-related disorder is selected from the group consisting essentially of general anxiety disorder, pathological or compulsive gambling disorder, compulsive eating, body dysmorphic disorder, hypochondriasis, pathologic grooming conditions, kleptomania, pyromania, attention deficit hyperactivity disorder and impulse control disorders.  
     
     
         21 . The method of  claim 19 , wherein said composition is selected from the group consisting essentially of GVG, gabapentin, valproic acid, topiramate, progabide, fengabide gamma-hydroxybutyric acid, tiagabine, acamprosate cetyl GABA or a pharmaceutically acceptable salt thereof, or an enantiomer or a racemic mixture thereof.  
     
     
         22 . The method of  claim 19 , wherein said mammal is a human and wherein said composition contains GVG in an amount from about 500 mg/day to about 5000 mg/day.  
     
     
         23 . The method of  claim 19 , wherein said mammal is a human and wherein said composition comprises gabapentin in an amount from about 600 mg/day to about 3600 mg/day.  
     
     
         24 . The method of  claim 19 , wherein said mammal is a human and said composition comprises valproic acid in an amount from about 500 mg/day to about 2500 mg/day.  
     
     
         25 . The method of  claim 19 , wherein said mammal is a human and wherein said composition comprises topiramate in an amount from about 100 mg/day to about 1000 mg/day.  
     
     
         26 . The method of  claim 20 , wherein said mammal is a human and wherein said composition comprises fengabine in an amount from about 700 mg/day to about 4000 mg/day.  
     
     
         27 . The method of  claim 19 , wherein said mammal is a human and wherein said composition comprises gamma-hydroxybutyric acid in an amount from about 700 mg/day to about 5000 mg/day.  
     
     
         28 . The method of  claim 19 , wherein said mammal is a human and wherein said composition comprises tiagabine in an amount from about 16 mg/day to about 56 mg/day.  
     
     
         29 . The method of  claim 19 , wherein said mammal is a human and wherein said composition comprises acamprosate in an amount from about 700 mg/day to about 3000 mg/day.